Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Reduction of risk of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in patients at risk. * Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. ## Adult Dosing * **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily. * **NSAID-Induced Gastric Ulcers:** 40 mg orally once daily for up to 8 weeks. * **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be increased as needed. Usual dose range is 40 mg to 240 mg per day. Doses > 120 mg daily should be divided and administered every 12 hours. ## Pediatric Dosing * **GERD and Erosive Esophagitis (6 to 16 years):** 20 mg orally once daily for up to 4 weeks. * **GERD and Erosive Esophagitis (1 month to 6 years):** Dosing varies significantly by weight and indication. Consult specific pediatric guidelines or product labeling. Doses typically range from 0.5 mg/kg to 1.5 mg/kg per day, divided once or twice daily. Maximum doses should not exceed adult maximums. ## Dose Adjustments No dose adjustment is generally needed for hepatic impairment. However, for severe hepatic impairment, the recommended daily dose is 20 mg orally once daily. No dose adjustment is needed for renal impairment. ## Contraindications * Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term use may be associated with vitamin B12 deficiency, hypomagnesemia, and an increased risk of Clostridium difficile-associated diarrhea and bone fractures. ## Key Drug Interactions * **Drugs that require gastric acid for absorption:** Absorption may be decreased (e.g., ketoconazole, itraconazole, posaconazole, erlotinib, rilpivirine, nelfinavir). * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. * **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may affect the metabolism of drugs like clopidogrel. ## Monitoring * Monitor for symptoms of GERD or ulcer healing. * Consider monitoring magnesium levels, especially in patients on long-term PPI therapy or concomitant diuretic use. * Assess for signs and symptoms of Clostridium difficile infection. ## Clinical Pearls * Administer pantoprazole oral suspension 30 minutes prior to a meal. * Do not crush or chew delayed-release tablets. * Intravenous pantoprazole should be administered over at least 15 minutes. * Long-term PPI use should be regularly re-evaluated to determine the need for continued therapy. *** *This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and institutional protocols before making any therapeutic decisions.*